← Leaderboards
Amir Horowitz
Icahn School Of Medicine At Mount Sinai
$1,902,078
Attributed
$3,566,323
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,566,323 · 4
By mechanism
R01$2,675,533 · 2
R21$890,790 · 2
Top collaborators
- John Sfakianos6 shared
- Won-Min Song1 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- John Sfakianos$1,435,953
- Lucas Ferrari De Andrade$1,481,935
- Nihal Mohamed$3,339,381
- Cheng Zhang$6,068,855
- Won-Min Song$2,566,218
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorCellsResponseResistance MechanismPathway InteractionsResistanceNewly DiagnosedKlrd1 GeneNatural Killer CellsGenesImmuneIntravesicalPhenotypeComplexBladder NeoplasmIn VitroCytometryHigh RiskMalignant NeoplasmsMediatingBcg LiveBindingCytokineMalignant Neoplasm Of Urinary Bladder
Grant awards (8)
Multi-scale analysis of Bacillus Calmette-Guérin (BCG) resistant tumor micro-environment in non-muscle invasive bladder cancer to identify novel therapeutic axis$684,877
R01 · FY2025 · CA
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer$667,174
R01 · FY2025 · CA · contact PI
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer$637,395
R01 · FY2024 · CA · contact PI
Identifying novel resistance mechanisms in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)$187,642
R21 · FY2024 · CA
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer$686,087
R01 · FY2023 · CA · contact PI
Identifying novel resistance mechanisms in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)$237,023
R21 · FY2023 · CA
Harnessing NK cell effector function for immunotherapies$211,875
R21 · FY2018 · AI · contact PI
Harnessing NK cell effector function for immunotherapies$254,250
R21 · FY2017 · AI · contact PI